SEC Form SC 13G/A filed by Dynavax Technologies Corporation (Amendment)
$DVAX
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/11/2025 | $15.00 → $12.00 | Neutral → Sell | Goldman |
2/1/2024 | $20.00 | Neutral | Goldman |
9/27/2022 | $22.00 | Mkt Outperform | JMP Securities |
1/6/2022 | $38.00 | Buy | Goldman |
12/29/2021 | $23.00 → $28.00 | Buy | HC Wainwright & Co. |
8/31/2021 | $20.00 → $23.00 | Buy | HC Wainwright & Co. |
8/6/2021 | $19.00 | Buy | Goldman Sachs |
8/5/2021 | $16.00 → $20.00 | Buy | HC Wainwright & Co. |